Quarterly report (Form 10-Q)
Boston Scientific 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
The 2026 Restructuring Plan is expected to result in total pre-tax charges of approximately $700 million to $800 million, of which approximately $600 million to $700 million is expected to result in future cash outlays, and reduce gross annual pre-tax expenses by approximately $500 million as program benefits are realized. We expect a portion of the savings to be reinvested in strategic growth initiatives.